Estrella Immunopharma, Inc.
ESLAEstrella Immunopharma is a clinical-stage biopharmaceutical company focused on developing next-generation T-cell therapies for the treatment of cancers and autoimmune diseases.
Table of contents
Earnings
Next report
Sep 2, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Estrella Immunopharma is a clinical-stage biopharmaceutical company focused on developing next-generation T-cell therapies for the treatment of cancers and autoimmune diseases. The company utilizes its proprietary ARTEMIS T-cell receptor platform to engineer therapies designed to mimic natural immune regulation, aiming to provide safer and more efficacious alternatives to traditional CAR-T treatments. Its primary value proposition lies in overcoming common limitations of cellular therapy, such as high toxicity, T-cell exhaustion, and the lack of effective targets for solid tumors.
Estrella is a clinical-stage developer positioned as a potential 'best-in-class' alternative to established CAR-T therapies by focusing on reduced toxicity and enhanced safety profiles.
Questions, answered.
- What is Estrella Immunopharma, Inc.'s market cap?
- Estrella Immunopharma, Inc. (ESLA) has a market capitalization of $33.3M and trades on NASDAQ.
- Who are Estrella Immunopharma, Inc.'s competitors?
- Estrella Immunopharma, Inc.'s key competitors include Fate Therapeutics, Mustang Bio, Kite Pharma, and others. These companies compete in similar markets and product categories.
- Who does Estrella Immunopharma, Inc. partner with?
- Estrella Immunopharma, Inc.'s notable partners include Eureka Therapeutics, Imugene, UC Davis Comprehensive Cancer Center, and others.
- What subsidiaries does Estrella Immunopharma, Inc. have?
- Estrella Immunopharma, Inc.'s subsidiaries include Estrella Biopharma, Inc..
- Where is Estrella Immunopharma, Inc. headquartered?
- Estrella Immunopharma, Inc. is headquartered in United States of America. It has been publicly traded since 2023.